Chargement en cours...

Phase II Evaluation of IPI-926, an Oral Hedgehog Inhibitor, in Patients with Myelofibrosis

The clinical safety and efficacy of IPI-926 was evaluated in 14 patients with myelofibrosis in a phase II study. Patients received 160-mg IPI-926 orally in continuous 28-day cycles. The median treatment duration was 5.1 months, and all patients had discontinued treatment by 7.5 months. Nine patients...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Leuk Lymphoma
Auteurs principaux: Sasaki, Koji, Gotlib, Jason R., Mesa, Ruben A., Newberry, Kate J., Ravandi, Farhad, Cortes, Jorge E., Kelly, Patrick, Kutok, Jeffery L., Kantarjian, Hagop M., Verstovsek, Srdan
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4919663/
https://ncbi.nlm.nih.gov/pubmed/25641433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.984703
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!